Reconvened meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and FOR Proposal Two at the Special Meeting to reconvene on January 16, 2025 EMERYVILLE, Calif. / Dec 19, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY)... Read More

Stockholders are urged to vote FOR Proposal One and Proposal Two before the reconvened Special Meeting scheduled for December 18 EMERYVILLE, Calif. / Dec 09, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders, You have the opportunity to approve a... Read More

Initial meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and Proposal Two EMERYVILLE, Calif. / Nov 22, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of... Read More

NovaBay urges stockholders to vote FOR all proxy proposals at the Special Meeting of Stockholders EMERYVILLE, Calif. / Nov 15, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company’s proxy proposals,... Read More

Online Avenova ® sales increase 14% for the quarter and 19% for the nine months Sales and marketing expenses declined 25% for the quarter and 18% for the nine months reflecting digital marketing optimization EMERYVILLE, Calif. / Nov 07, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. “Avenova sales through the... Read More

EMERYVILLE, Calif. / Nov 06, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) (“NovaBay” or the “Company”) today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to increase the base purchase price for the Company’s eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the... Read More

EMERYVILLE, Calif. / Oct 29, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC (“Refresh”) for an affiliate of Refresh to acquire the Company’s Avenova ® brand and related assets is a “Superior Proposal” to the Company’s asset... Read More

This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products BLUE BELL, Pa. , Sept. 20, 2024 /PRNewswire/ -- Acumen Health Holdings, LLC , a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion animals, announced today that its subsidiary, PRN Physician Recommended Nutriceuticals, LLC, has entered... Read More

EMERYVILLE, Calif. / Sep 20, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a definitive asset purchase agreement (the “Agreement”) with PRN Physician Recommended Nutriceuticals , LLC (“PRN”) to sell the assets of its Avenova ® brand and business for $9.5 million in cash. The transaction has been approved by the Company’s board of... Read More

Eyecare product revenue increased 8% driven by higher sales of Avenova ® -branded products through online channels Sales and marketing expenses declined 13% reflecting efficient growth through digital marketing optimization Balance sheet strengthened with $3.9 million financing in July Conference call begins at 4:30 p.m. Eastern time today EMERYVILLE, Calif. / Aug 13, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc.... Read More

EMERYVILLE, Calif. / Aug 01, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration:... Read More

EMERYVILLE, Calif. / Jul 30, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova ® -branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over Prime Day 2022. “We reached another new sales record during the 2024 Amazon Prime Day event... Read More

EMERYVILLE, Calif. / Jul 29, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants for gross proceeds of approximately $3.87 million, prior to deducting underwriting discounts and commissions... Read More

EMERYVILLE, Calif. / Jul 26, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”), today announced the pricing of its underwritten public offering of 3,200,380 shares of common stock (or pre-funded warrants in lieu thereof), 3,200,380 Series F-1 warrants to purchase up to 3,200,380 shares of common stock, 3,200,380 Series F-2 warrants to purchase up to 3,200,380 shares of... Read More

EMERYVILLE, Calif. / Jul 16, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova ® -branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024. “Prime Day has been a highly productive event for NovaBay in past years and conveniently falls during National Dry Eye Awareness Month when there is increasing focus on this chronic... Read More

Eyecare revenue for both the second quarter and the first half of 2024 increased by 9% over the comparable prior-year periods, driven by higher online sales The number of Avenova ® subscribers on Amazon increased by 64% since the beginning of 2023 and by 123% since the beginning of 2022 EMERYVILLE, Calif. / Jul 11, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”)... Read More

Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, 0.05% to U.S. eyecare professionals EMERYVILLE, Calif. & NEW YORK / Jul 01, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company... Read More

EMERYVILLE, Calif. / Jun 28, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova ® -branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye Awareness Month is intended to recognize the importance of eye health to overall health, and to... Read More

EMERYVILLE, Calif. / Jun 07, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards. “I’m pleased to report on our forward momentum. By divesting an unprofitable business segment earlier this year, we’re now able to focus solely on... Read More

Announces a 1-for-35 Reverse Stock Split and Receipt of NYSE American Notice Regarding Stockholders’ Equity EMERYVILLE, Calif. / May 29, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company’s Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission (the “SEC”) were approved by... Read More

Approximately 16 million Americans suffer from dry eye disease with the U.S. market for dry eye treatment projected to reach $4.86 billion by 2030 EMERYVILLE, Calif. / May 13, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova ® product bundles... Read More

Net product sales increased 13% over the prior year driven by higher sales of Avenova ® -branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sales for Avenova-branded products on Amazon.com reached new all-time records in March and April Conference call begins at 4:30 p.m. Eastern time today... Read More

Ordered product sales of Avenova ® -branded products on Amazon.com set back-to-back records in March and April 2024 Enhanced marketing program provides potential for additional growth in the U.S. dry eye disease treatment market projected to reach nearly $5 billion by 2030 EMERYVILLE, Calif. / May 07, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing... Read More

EMERYVILLE, Calif. / May 03, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants... Read More

EMERYVILLE, Calif. / Apr 22, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova ® brand while engaging with customers to drive online sales of Avenova products.... Read More

EMERYVILLE, Calif. / Apr 19, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by... Read More

Growth driven by efficient Avenova ® direct-to-consumer e-marketing programs EMERYVILLE, Calif. / Apr 17, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is... Read More

Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova ® physician dispensed and OTC channels, and from branded wound care products Sales and marketing expenses for the quarter declined 27% reflecting digital marketing optimization Divestiture of skincare segment expected to bolster cash position and reduce operating expenses Continued execution on eyecare growth... Read More

EMERYVILLE, Calif. / Mar 25, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration:... Read More

DERMAdoctor sale reduces operating expenses and bolsters cash EMERYVILLE, Calif. / Mar 14, 2024 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAdoctor ® skincare business including all product inventory for approximately $1.0 million in cash.... Read More

EMERYVILLE, Calif. / Jan 30, 2024 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova ® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022. In... Read More

EMERYVILLE, Calif. / Dec 06, 2023 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here . In September 2023 NovaBay commercially launched its... Read More

Net product revenue from Avenova ® -branded eyecare products grew 7% year-over-year, reflecting an increased contribution from the physician dispensed channel Sales and marketing expenses declined 7% versus the prior year through continued optimized digital marketing programs Operating loss for the first nine months of 2023 narrowed by 16% from the prior year Marketing activities are underway to promote differentiated,... Read More

EMERYVILLE, Calif. / Nov 02, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Thursday, November 9, 4:30 p.m. ET / 1:30 p.m. PT... Read More

EMERYVILLE, Calif. / Oct 11, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of chronic dry eye with Avenova ® -branded products. Through the new Avenova Loyalty... Read More

EMERYVILLE, Calif. / Oct 02, 2023 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8 th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham... Read More

EMERYVILLE, Calif. & POMPANO BEACH, Fla. / Sep 14, 2023 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’s (OTC: BSEM) proprietary process and is intended for use as a... Read More

EMERYVILLE, Calif. & POMPANO BEACH, Fla. / Sep 11, 2023 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Amniotic Tissue Allograft provides a... Read More

Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital marketing programs Operating loss decreased by 37% year-over-year Conference call begins at 4:30 p.m. Eastern time today EMERYVILLE, Calif. / Aug 10, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE... Read More

EMERYVILLE, Calif. / Aug 08, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2023 after market close on Thursday, August 10, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Thursday, August 10, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration:... Read More

EMERYVILLE, Calif. / Jul 14, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that sales of Avenova ® -branded products reached a new record during the Amazon Prime Day event held July 11-12, 2023, with sales increasing 22% over Prime Day 2022 and 43% over Prime Day 2021. “Sales of Avenova... Read More

EMERYVILLE, Calif. / Jul 10, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces special pricing on Avenova ® -branded products to Amazon prime members during Prime Day 2023, being held July 11-12. “Prime Day offers a significant opportunity to increase sales through this important channel,”... Read More

EMERYVILLE, Calif. / Jun 28, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova ® -branded eyecare products to customers and eyecare professionals throughout July in support of National Dry... Read More

EMERYVILLE, Calif. / Jun 20, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will showcase its Avenova ® -branded eyecare products at the 126 th Annual American Optometric Association (AOA) Congress & 55 th Annual American Optometric Student Association ( AOSA) Conference:... Read More

Chief Product Officer Dr. Audrey Kunin to showcase KP Duty combo with supercharged exfoliators and moisturizers to help rapidly lift away dry, rough bumps and reveal healthier looking skin EMERYVILLE, Calif. / Jun 12, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product... Read More

MIAMI, May 30, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 57th Emerging Growth Conference on May 31, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the... Read More

EMERYVILLE, Calif. / May 24, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, Chief Executive Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, May 31, 2023 at 1:10 p.m. Eastern time (10:10 a.m. Pacific time). To attend the... Read More

Sales of eyecare products increased with higher sales of Avenova Spray related companion products Sales and marketing spend reduced by 17% through optimized digital marketing programs Launched DERMAdoctor ® Comfort + Joy Psoriasis Therapeutic Moisturizing Cream Conference call begins at 4:30 p.m. Eastern time today EMERYVILLE, Calif. / May 11, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY)... Read More

NASHVILLE, Tenn. & EMERYVILLE, Calif. / May 05, 2023 / Business Wire / PhaseOne Health announces it has provided PhaseOne Skin and Wound Cleanser (PhaseOne) as part of a $3 million donation of medical supplies to Ukraine in partnership with the nonprofit HelpingUkraine.us . Formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid, PhaseOne (0.025% hypochlorous acid solution) is a... Read More

EMERYVILLE, Calif. / May 04, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Thursday, May 11, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants... Read More

EMERYVILLE, Calif. / May 01, 2023 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1 million order for NovaBay’s NeutroPhase Skin and Wound Cleanser . NovaBay has fulfilled this order and expects to recognize this revenue in the... Read More

EMERYVILLE, Calif. / Apr 27, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announced today that it has entered into a securities purchase agreement with institutional accredited investors (“Purchasers”) in connection with a private placement to issue secured senior convertible debentures (the “Debentures”) and two series of new warrants exercisable for NovaBay common... Read More

First DERMAdoctor product specifically formulated for psoriasis will be exclusively available on Jane & Shawn’s Beauty Secrets tonight at 10 p.m. Eastern time EMERYVILLE, Calif. / Apr 21, 2023 / Business Wire / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare,... Read More

Product sales increased 15% for the quarter and 41% for the year, driven by increasingly diversified revenue streams Wound care revenue increased 143% year over year Digital marketing program optimization continued to drive higher product sales on lower marketing spend Eyecare portfolio recently expanded with the introduction of the Avenova ® oral supplement and Eyeganics Organic Tears Conference call begins at 4:30 p.m.... Read More

EMERYVILLE, Calif. / Mar 23, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time : Thursday, March 30, 4:30 p.m. ET / 1:30 p.m. PT... Read More

EMERYVILLE, Calif. & KIRKWOOD, Mo. / Mar 14, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel . Organic Tears has no additives or artificial chemicals and is the only lubricant eye drop certified by the USDA as 100% organic and preservative-free.... Read More

EMERYVILLE, Calif. / Mar 07, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright ® , a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and high quality, natural triglyceride omega-3 oils to comfort dry eyes and support overall eye health. Avenova Eye Health Support is... Read More

EMERYVILLE, Calif. / Feb 06, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor ® ’s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on “It Takes Two With Mary & Sandra” at 2 p.m.... Read More

EMERYVILLE, Calif. / Jan 31, 2023 / Business Wire / NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website . “We closed 2022 with one of our best quarters ever for Avenova ® unit sales. Looking into... Read More

PhaseOne is uniquely formulated with NovaBay Pharmaceuticals’ unique and proprietary hypochlorous acid PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals ’ (NYSE American: NBY)... Read More